"changes in turnover" is a correct and usable phrase in written English.
It can be used when referring to changes, either increases or decreases, in the amount of money that a company takes in from sales. For example, "The company's CEO reported that there had been significant changes in turnover since implementing the new marketing strategies."
This is statistically useful for looking at changes in house prices but not the dollar amount of an average house given the possibility that a simple median price risks being distorted by changes in turnover at either the top or bottom end of the market.
In other words: when CVT is less crucial to firm productivity, employers might react more sensitively to changes in turnover.
Given the average scope of turnover (9.0percentt in the full sample), realistic changes in turnover rates would thus affect CVT incidence only slightlys.
Other than that, the system is by and large buffered against changes in turnover rates.
Slight changes in turnover rates influence the dynamic behavior of CRNs and now, we wish to carry out a similar procedure for the apoptosis model proposed.
The impact of mRNA stability control on normal and malignant myelopoiesis has been less well characterized despite evidence that changes in turnover rates of certain mRNAs can dramatically affect cellular behavior (for review, [35]).
Mitochondria play an important role in the development of malfunction of various organs, such as heart, liver, and kidney, in a mode that involves changes in turnovers of ATP, ROS, Ca2+, and release of proapoptotic proteins.
Dnm1-GFP levels are relatively stable over a 24 h period with little change in turnover (Supplementary Material, Fig. S4B).
Therefore the relocation of the PPXD and contact with NBD2 communicates a change in turnover and affinity for ATP, corresponding to the activation by SecYEG.
In contrast to yeast where the magnitude of change in turnover at the promoter is approximately the same as in the gene body (PMID: 22807688; 22922743), the absence of mammalian Chd1 activity leads to a much greater reduction in promoter histone turnover.
Increasing interest in mechanism-based approaches has also prompted efforts towards model parameterization that enables the distinction between drug- and system or disease-specific properties, e.g., differences in the affinity to target receptors, maturational profiles and change in turnover rate of an enzyme with disease progression.
